Evidence map›Paper›PMID 30925916›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells.

Mahrou Vahabi, Claudio Pulito, Andrea Sacconi, Sara Donzelli, Marco D'Andrea, Valentina Manciocco, Raul Pellini, Paola Paci, Giuseppe Sanguineti, Lidia Strigari and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 114 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. miR-96-5p expression is sufficient to induce and maintain the senescent cell fate in the absence of stress.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  14. RETRACTED: PTEN Deficiency Induced by Extracellular Vesicle miRNAs fromInternational journal of molecular sciences · 2024
    Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 6 institutions in 4 countries.

Mahrou VahabiOncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Claudio PulitoOncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Andrea SacconiOncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Sara DonzelliOncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Marco D'AndreaUnit of Radiotherapy, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Valentina MancioccoUnit of Otolaryngology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Raul PelliniUnit of Otolaryngology, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Paola PaciInstitute for Systems Analysis and Computer Science "A. Ruberti", National Research Council, Rome, Italy.
Giuseppe SanguinetiUnit of Radiotherapy, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Lidia StrigariLaboratory of Medical Physics and Expert Systems, IRCCS-Regina Elena National Cancer Institute, Rome, Italy.
Giuseppe SprianoUnit of Otorhinolaryngology, Humanitas University, Milan, Italy.
Paola MutiDepartment of Oncology, Juravinski Cancer Center, McMaster University, Hamilton, Canada.
Pier Paolo PandolfiCancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Harvard Medical School, Boston, MA, USA.
Sabrina StranoOncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy.
Shahrokh SafarianCell and Molecular Biology Department, School of Biology, College of Science, University of Tehran, Tehran, 1417614411, Iran. safarian@khayam.ut.ac.ir.
Federica GanciOncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy. federica.ganci@ifo.gov.it.
Giovanni BlandinoOncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer Institute, 00144, Rome, Italy. giovanni.blandino@ifo.gov.it.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Tehran · IRBeth Israel Deaconess Medical Center · USHumanitas University · ITMcMaster University · CANational Research Council · IT

Funding

Associazione Italiana per la Ricerca sul Cancro IG 2017
6 · The paper itself

Abstract

backgroundHead and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer worldwide. They are typically characterized by a high incidence of local recurrence, which is the most common cause of death in HNSCC patients. TP53 is the most frequently mutated gene in HNSCC and patients carrying TP53 mutations are associated with a higher probability to develop local recurrence. MiRNAs, which are among the mediators of the oncogenic activity of mt-p53 protein, emerge as an appealing tool for screening, diagnosis and prognosis of cancer. We previously identified a signature of 12 miRNAs whose aberrant expression associated with TP53 mutations and was prognostic for HNSCC. Among them miR-96-5p emerges as an oncogenic miRNAs with prognostic significance in HNSCC.

methodsTo evaluate the oncogenic role of miR-96-5p in a tumoral context, we performed colony formation, cell migration and cell viability assays in two HNSCC cell lines transfected for miR-96-5p mimic or inhibitor and treated with or without radio/chemo-therapy. In addition, to identify genes positively and negatively correlated to miR-96-5p expression in HNSCC, we analyzed the correlation between gene expression and miR-96-5p level in the subset of TCGA HNSCC tumors carrying missense TP53 mutations by Spearman and Pearson correlation. To finally identify targets of miR-96-5p, we used in silico analysis and the luciferase reporter assay to confirm PTEN as direct target.

resultsOur data showed that overexpression of miR-96-5p led to increased cell migration and radio-resistance, chemotherapy resistance in HNSCC cells. In agreement with these results, among the most statistically significant pathways in which miR-96-5p is involved, are focal Adhesion, extracellular matrix organization and PI3K-Akt-mTOR-signaling pathway. As a direct target of miR-96-5p, we identified PTEN, the main negative regulator of PI3K-Akt signalling pathway activation.

conclusionsThese results highlight a new mechanism of chemo/radio-resistance insurgence in HNSCC cells and support the possibility that miR-96-5p expression could be used as a novel promising biomarker to predict radiotherapy response and local recurrence development in HNSCC patients. In addition, the identification of pathways in which miR-96-5p is involved could contribute to develop new therapeutic strategies to overcome radio-resistance.

Indexed as

Drug Resistance, NeoplasmRadiation Tolerance3' Untranslated RegionsCell Line, TumorCell MovementCell ProliferationCell SurvivalGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansMicroRNAsPrognosisPTEN PhosphohydrolaseSignal TransductionSquamous Cell Carcinoma of Head and NeckSurvival Analysis3' Untranslated RegionsMicroRNAsMIRN96 microRNA, humanPTEN PhosphohydrolasePTEN protein, humanChemotherapyHead and neck cancerLocal recurrenceMigrationmiR-96-5pmiRNAsPI3K-Akt signalling pathwayPTENRadiotherapyTP53 mutations

Identifiers

PMID30925916
PMCPMC6440033
OpenAlexW2944296806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.